Biotech News

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Personalis (PSNL)Personalis2026-06-25 13:46 ESTConference / presentation

FREMONT, Calif. --(BUSINESS WIRE)--Feb. 17, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46 th Annual Healthcare Conference on Tuesday, March 3, 2026 at the Boston Marriott

Open original release

Related news

PSNLPersonalis2026-06-25 13:46 EST

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

PSNLPersonalis2026-06-25 13:46 EST

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

PSNLPersonalis2026-06-25 13:46 EST

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

PSNLPersonalis2026-06-25 13:46 EST

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

PSNLPersonalis2026-06-25 13:46 EST

Personalis to Participate in Upcoming Investor Events

PSNLPersonalis2026-06-25 13:46 EST

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

PSNLPersonalis2026-06-25 13:46 EST

Personalis Reports First Quarter Results and Recent Highlights

PSNLPersonalis2026-06-25 13:46 EST

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

PSNLPersonalis2026-06-25 13:46 EST

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

PSNLPersonalis2026-06-25 13:46 EST

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

View all latest news

Personalis

Personalis is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

PSNLPersonalis2026-06-26 16:06 EST

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

PSNLPersonalis2026-06-26 16:06 EST

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

PSNLPersonalis2026-06-26 16:06 EST

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

PSNLPersonalis2026-06-26 16:06 EST

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

PSNLPersonalis2026-06-26 16:06 EST

Personalis to Participate in Upcoming Investor Events

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States